Tsuruha Holdings Inc.

3391.T
Pharmaceutical Retailers
2026/01/16 Updated
Market Cap: $7.5B (¥1.2T)
Stock Price: $16.41 (¥2,600)
Exchange Rate: 1 USD = ¥158.48

Notice Regarding Revision of Full-Year Consolidated Earnings Guidance and Year-End Dividend Forecast

Revised full-year consolidated earnings guidance for the fiscal year ending February 2026 to net sales of 1,453,000 million yen, operating income of 63,300 million yen, and net income attributable to owners of parent of 39,500 million yen. Year-end dividend forecast revised to 23.00 yen per share after stock split.

Importance:
Page Updated: January 8, 2026
IR Disclosure Date: January 8, 2026

Key Figures

  • Net Sales: 1,453,000 million yen (Full-Year Consolidated Earnings Guidance for FY ending February 2026)
  • Net Income Attributable to Owners of Parent: 39,500 million yen (Full-Year Consolidated Earnings Guidance for FY ending February 2026)
  • Year-End Dividend Forecast: 23 yen 00 sen (Post Stock Split, End of FY February 2026)

AI要約

Regarding Revision of Earnings Guidance

The full-year consolidated earnings guidance for the fiscal year ending February 2026 has been revised to net sales of 1,453,000 million yen, operating income of 63,300 million yen, ordinary income of 63,600 million yen, net income attributable to owners of parent of 39,500 million yen, and net income per share of 133.66 yen. The revision is due to the impact of making Welcia Holdings Co., Ltd. a consolidated subsidiary following business integration on December 1, 2025, goodwill recording, an increase in special gains, and the inclusion of fourth-quarter results.

Regarding Revision of Dividend Forecast

The year-end dividend forecast has been revised from undecided to 23.00 yen (post stock split). The total annual dividend amount is not directly comparable due to the impact of the stock split. The shareholder return policy is under review, and the dividend level reflects earnings trends after the business integration with Welcia Holdings. Enhancements to the shareholder benefits program have also been announced concurrently.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.